Adagene ADR Aktie

Adagene will provide muzastotug (ADG126) for a Phase 1 combination trial with Incyte’s INCA33890 targeting MSS colorectal cancer, planned to start in 2026 and focusing on third-line patients with and without liver metastases. Incyte will sponsor and run the study while Adagene supplies the clinical material. The collaboration expands muzastotug’s clinical program after prior combination data showed a 31% overall response rate in certain high-dose cohorts and a median overall survival of 19.8 months in 10 mg/kg cohorts when combined with pembrolizumab. » Plus sur finance.yahoo.com

Adagene has priced a guaranteed public offering of 18,666,000 ADS at $3.75 per ADS, implying gross proceeds of approximately $70.0 million. Each ADS represents 1.25 common shares; the offering price is below the current market price and equals the volume-weighted 30-day average. Closing is expected on April 6, 2026; Leerink Partners and LifeSci Capital are joint bookrunners. Investors include both new and existing funds; the company remains unprofitable despite cash on hand and is currently rated overvalued by InvestingPro. » Plus sur de.investing.com

Adagene released updated data from its phase‑1b/2 study of Muzastotug plus pembrolizumab in microsatellite‑stable colorectal cancer without liver metastases: in the combined 20 mg/kg cohorts a confirmed overall response rate of 31% was achieved versus 13% in the 10 mg/kg cohorts (data set: 67 patients). Median progression‑free survival was 6.7 months (20 mg/kg) versus 4.8 months (10 mg/kg); the one‑year survival rate was 80.8% and 70.1%, respectively. Safety data showed a discontinuation rate of 4%, no dose‑limiting toxicities and no treatment‑related grade‑4/5 events; grade‑3 adverse events occurred in 15% (10 mg/kg) and 38% (20 mg/kg). The FDA has granted Muzastotug plus pembrolizumab fast‑track status; a randomized phase‑2 trial is recruiting and results are expected in H1 2027. Despite the progress, Adagene remains unprofitable with a market capitalization of $217m, and the stock rose sharply last year. » Plus sur de.investing.com